Chemokines as Therapeutic Targets in Cardiovascular Disease

Area of Science:

• Cardiovascular Science
• Inflammation Research
• Drug Discovery

Background:

• Atherosclerotic cardiovascular disease (ASCVD) incidence and impact are increasing globally.
• Lowering inflammation, as shown by the CANTOS trial, offers a viable therapeutic avenue.
• Understanding inflammation mechanisms, such as leukocyte recruitment, is crucial for developing new treatments.

Purpose of the Study:

• To provide an overview of recent developments in targeting chemokines and macrophage migration inhibitory factor (MIF) for inflammatory diseases.
• To explore innovative therapeutic approaches for chemokine-based anti-inflammatory treatments.
• To discuss the potential of targeting leukocyte trafficking in ASCVD.

Main Methods:

• Review of recent scientific literature on chemokines and MIF.
• Analysis of therapeutic strategies targeting leukocyte recruitment.
• Discussion of challenges and advancements in drug development for chemokine-based therapies.

Main Results:

• Chemokines are key regulators of leukocyte trafficking and remain attractive therapeutic targets.
• Innovative approaches are emerging for developing chemokine-based anti-inflammatory drugs.
• Macrophage migration inhibitory factor (MIF) is also discussed as a relevant target.

Conclusions:

• Targeting inflammation through chemokines and MIF offers a promising strategy for managing ASCVD.
• Continued research and development in chemokine-based therapies could lead to the first approved treatments.
• Focusing on leukocyte recruitment mechanisms presents a feasible path for novel anti-inflammatory interventions.